Reckitt Benckiser Group/£RKT

08:00
10:10
12:15
14:25
16:30
1D1W1MYTD1Y5YMAX

About Reckitt Benckiser Group

Reckitt Benckiser Group is a British multinational consumer goods company headquartered in Slough, England. It operates within the health, hygiene, and home product categories. The company's key brands include Dettol, Lysol, Durex, and Nurofen, offering a wide range of products from disinfectants to pharmaceuticals. Founded in 1999 through the merger of Reckitt & Colman and Benckiser, the company has a significant global presence, with operations in over 60 countries. Reckitt Benckiser's strategic strength lies in its diversified product portfolio and strong brand recognition, which facilitate its competitive positioning in various consumer markets.

Ticker

£RKT

Primary listing

LSE

Employees

37,900

RKT Metrics

BasicAdvanced
£40B
32.53
£1.80
0.07
£2.06
3.52%

What the Analysts think about RKT

Analyst ratings (Buy, Hold, Sell) for Reckitt Benckiser Group stock.

Bulls say / Bears say

Reckitt's like-for-like net sales grew 7% in the third quarter, with a 15.5% jump in emerging markets highlighting strong demand in those regions. (Reuters)
In the second quarter of 2025, Reckitt’s core brands posted 5.3% revenue growth, beating analyst estimates and prompting the company to raise its full-year like-for-like net revenue growth forecast to 3%–4%. (WSJ)
Selling a majority stake in Essential Home for $4.8 billion enabled a $2.2 billion special dividend and a £1 billion share buyback, allowing Reckitt to focus more on its higher-margin Powerbrands. (Reuters)
Reckitt warned that market volatility may delay the planned sale of its Essential Home division, where first-quarter revenues fell 7%, casting doubt on transaction timing. (FT)
Total net revenue in the second quarter of 2025 declined by 3.8%, as weaknesses in non-core businesses such as Mead Johnson and Essential Home offset the gains from core brands. (WSJ)
Analysts criticized the valuation for the Essential Home sale as disappointing, suggesting it missed expectations by up to £1 billion and that keeping a 30% stake prevents a clear strategic exit. (FT)
Data summarised monthly by Lightyear AI. Last updated on 4 Nov 2025.

RKT Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

RKT Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy £RKT

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs